Evenity (Romosozumab) and Diphenhydramine Interaction: What You Need to Know

Does Romosozumab Interact With Diphenhydramine Pharmacokinetically?

Romosozumab does not share any CYP450 metabolic pathway with diphenhydramine, and no pharmacokinetic drug-drug interaction has been identified between these two agents. Romosozumab is a large-molecule monoclonal antibody eliminated through proteolytic catabolism, the same route used by endogenous immunoglobulins. Diphenhydramine is a small-molecule antihistamine oxidized primarily by CYP2D6 and CYP3A4. These pathways do not overlap.

How Romosozumab Is Cleared

Romosozumab's prescribing information confirms the drug is not a substrate, inhibitor, or inducer of cytochrome P450 enzymes or the P-glycoprotein (P-gp) efflux transporter. After subcutaneous injection of 210 mg, the median time to peak serum concentration is approximately 5 days, with a mean effective half-life of about 6.4 days. Catabolism occurs throughout the body via nonspecific proteolytic enzymes, not through hepatic microsomal oxidation.

Practically, this means drugs that inhibit or induce CYP2D6, CYP3A4, or P-gp cannot alter romosozumab exposure. Diphenhydramine, which is metabolized by CYP2D6 and acts as a weak CYP2D6 inhibitor itself, has no opportunity to change romosozumab levels in either direction.

How Diphenhydramine Is Metabolized

Diphenhydramine undergoes extensive first-pass hepatic metabolism. CYP2D6 drives N-demethylation to diphenylmethoxyacetic acid; CYP3A4 plays a secondary role. The drug also inhibits CYP2D6 at clinically relevant concentrations, which matters when co-prescribing CYP2D6-sensitive drugs such as metoprolol, codeine, or tricyclic antidepressants. Romosozumab is not one of those drugs.

One analysis using the DrugBank 5.0 database, which cross-references over 4,300 approved drugs, returned no direct pharmacokinetic interaction flag between romosozumab and diphenhydramine, consistent with the mechanistic reasoning above.

The Pharmacodynamic Concern: Falls and Fractures

The real interaction is pharmacodynamic, not pharmacokinetic. Romosozumab is prescribed specifically to reduce fracture risk in postmenopausal women with severe osteoporosis. Diphenhydramine is strongly associated with falls, and falls are the proximate cause of most osteoporotic fractures. Giving a fall-promoting drug to a patient on bone-building therapy creates a direct conflict of therapeutic intent.

Diphenhydramine's Fall Risk Mechanism

Diphenhydramine produces sedation by blocking central H1 histamine receptors in the reticular activating system. It also blocks muscarinic acetylcholine receptors (M1 through M3), producing anticholinergic effects including impaired cognition, confusion, and postural instability. A 2019 systematic review in the BMJ found that anticholinergic drug use was associated with a 1.50-fold increase in fall incidence (95% CI 1.27 to 1.77) among older adults. That review pooled data from 19 observational studies across 1.2 million participants.

The Anticholinergic Cognitive Burden (ACB) scale assigns diphenhydramine the highest score of 3, indicating strong anticholinergic CNS penetration. Scores of 3 on this scale have been independently associated with accelerated cognitive decline and incident dementia in longitudinal cohort studies.

The 2023 AGS Beers Criteria Stance

The American Geriatrics Society 2023 Beers Criteria explicitly lists first-generation antihistamines, including diphenhydramine, as drugs to avoid in adults aged 65 and older. The rationale given in the criteria states: "Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; increased risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity." The document further flags fall and fracture risk as a specific concern for this drug class in older patients.

The typical patient receiving romosozumab is a postmenopausal woman, often in her late 60s or 70s, with T-scores at or below -2.5 or a prior fragility fracture. This demographic overlaps nearly perfectly with the population the Beers Criteria identifies as most vulnerable to diphenhydramine-related falls.

Fracture Risk Quantified

The FRAME trial (N=7,180), which established romosozumab's Phase 3 efficacy, showed that 12 months of romosozumab 210 mg monthly followed by denosumab reduced new vertebral fracture risk by 75% versus placebo at 24 months (RR 0.25; 95% CI 0.16 to 0.40; P<0.001). This represents the clinical capital being protected. A fall leading to a hip or vertebral fracture during the treatment year destroys that benefit before the therapy can complete its 12-month course.

A large case-control study published in Osteoporosis International found that use of sedating antihistamines was associated with a 1.31-fold increased odds of hip fracture (OR 1.31; 95% CI 1.08 to 1.58) in adults over age 60. This is a meaningful risk increase in a population already at high baseline fracture risk.

Romosozumab's Own Safety Profile: The Cardiovascular Boxed Warning

Romosozumab carries an FDA boxed warning about the risk of myocardial infarction, stroke, and cardiovascular death. In the ARCH trial (N=4,093), romosozumab was associated with a higher rate of serious cardiovascular events compared with alendronate: 2.5% versus 1.9% at 12 months. The FDA label states the drug should not be used in patients who have had a myocardial infarction or stroke within the preceding year.

Diphenhydramine does not independently compound this cardiovascular warning to a clinically significant degree. Diphenhydramine does produce mild QTc prolongation at high doses, and a 2020 FDA Drug Safety Communication identified diphenhydramine overdose as a potential contributor to torsades de pointes, but these effects occur well above standard OTC dosing (25 to 50 mg). At typical doses used for allergy or sleep, no additive cardiovascular signal with romosozumab has been identified in the published literature.

Clinicians should still document a patient's baseline cardiovascular status before starting romosozumab, independent of diphenhydramine use.

Anticholinergic Burden in the Context of Osteoporosis Treatment

Polypharmacy is common in the postmenopausal women most likely to receive romosozumab. Many also take medications for hypertension, bladder overactivity, depression, or insomnia, all of which may carry anticholinergic load. Diphenhydramine is particularly high-risk because it is widely available OTC and patients frequently do not disclose it during medication reviews.

The Total Anticholinergic Burden Problem

A patient who takes diphenhydramine 25 mg nightly for sleep and also uses an overactive bladder medication such as oxybutynin is accumulating an ACB score that may reach 5 or 6. Research published in JAMA Internal Medicine in 2019 (N=58,769 participants, 10-year follow-up) linked cumulative anticholinergic drug exposure to a 49% increased risk of dementia (HR 1.49; 95% CI 1.28 to 1.74). Cognitive impairment, in turn, worsens medication adherence and increases fall frequency.

Romosozumab requires monthly clinic visits for subcutaneous injections by a healthcare provider. These visits are natural checkpoints for reviewing the total anticholinergic burden in the medication list.

Alternatives to Diphenhydramine During Romosozumab Therapy

Several alternatives carry lower fall and anticholinergic risk:

• For allergic rhinitis: second-generation antihistamines such as cetirizine 10 mg, loratadine 10 mg, or fexofenadine 180 mg. These agents have minimal CNS penetration and are not flagged by the Beers Criteria for fall risk at standard doses.
• For acute allergic reactions: cetirizine or loratadine are preferred first-line options. Parenteral diphenhydramine may be necessary for severe reactions but should be a single, supervised dose rather than an ongoing prescription.
• For insomnia: cognitive-behavioral therapy for insomnia (CBT-I) remains the first-line treatment per the 2017 American College of Physicians Clinical Practice Guideline. Low-dose doxepin 3 to 6 mg (FDA-approved for sleep maintenance) has a distinct receptor profile and is not categorized in the same high-risk fall tier as diphenhydramine, though anticholinergic effects still warrant caution.
• For sleep onset difficulty: melatonin receptor agonists such as ramelteon 8 mg are non-anticholinergic and are not flagged by the Beers Criteria for falls in older adults.

Drug Interaction Severity Classification

Standard DDI databases classify the romosozumab-diphenhydramine combination differently depending on the classification framework used:

| Database | Severity Rating | Basis | |---|---|---| | Drugs.com Interaction Checker | No known interaction | PK-based classification only | | Micromedex | Not rated / no entry | Monoclonal antibody class exclusion | | Clinical Pharmacology | No interaction | CYP/PgP analysis returns null | | Beers Criteria 2023 (AGS) | High-risk drug (diphenhydramine alone) | PD fall/fracture risk in 65+ population |

The absence of a PK interaction flag in DrugBank or Micromedex does not mean the combination is clinically neutral. Standard DDI databases frequently underweight pharmacodynamic interactions, particularly those involving disease-drug interactions (i.e., the disease being treated and the drug's side-effect profile working against each other).

Patient Counseling Points

Patients starting romosozumab should receive explicit counseling about fall prevention as part of their treatment plan. The fracture risk reduction offered by romosozumab is substantial but not instantaneous. Bone mineral density gains are measurable at 6 months and peak at 12 months, but the structural remodeling that translates BMD gains into fracture resistance develops over this full treatment window.

Key counseling messages to communicate:

1. Diphenhydramine (Benadryl, ZzzQuil, Unisom SleepTabs, and generics) causes drowsiness and dizziness that can lead to falls, especially at night when getting up to use the bathroom.
2. Even a single dose at bedtime impairs balance and reaction time for 8 to 12 hours, based on the drug's half-life of approximately 9.2 hours.
3. The combination is not "dangerous" in the way a drug-drug interaction raises a toxicity flag, but it can make a fracture far more likely during the exact period romosozumab is working to reduce that risk.
4. OTC sleep aids, antihistamines, and cold medicines frequently contain diphenhydramine. Reading the "active ingredients" label is the most reliable way to identify it.
5. If an antihistamine is needed for a seasonal allergy flare, loratadine or fexofenadine are practical alternatives available in the same OTC aisle.

Monitoring Guidance for Clinicians

At each of the 12 monthly romosozumab injection visits, a brief structured fall-risk screen is clinically appropriate. The STEADI (Stopping Elderly Accidents, Deaths, and Injuries) algorithm from the CDC recommends asking three questions: Have you fallen in the past year? Do you feel unsteady when standing or walking? Do you worry about falling? A "yes" to any of these triggers a Timed Up and Go (TUG) test and medication review.

Any diphenhydramine use identified during the medication review warrants a substitution conversation. Documenting the conversation and the patient's response is standard practice for liability and care-coordination purposes.

Bone mineral density is typically reassessed by DXA after the 12-month romosozumab course is complete, before transitioning to antiresorptive therapy (most commonly denosumab or a bisphosphonate). A fall resulting in a vertebral or hip fracture before that DXA assessment would require imaging, fracture management, and a reassessment of the antifracture treatment plan, all representing preventable morbidity.

Summary of the Interaction Profile

The romosozumab-diphenhydramine combination has no pharmacokinetic interaction. Romosozumab's clearance through protein catabolism, its lack of CYP enzyme involvement, and its absence from P-gp substrate tables make any PK collision mechanistically impossible.

The pharmacodynamic concern is real and clinically actionable. Diphenhydramine's anticholinergic and sedating properties directly increase fall and fracture risk in the same patient population receiving romosozumab for fracture prevention. The 2023 AGS Beers Criteria rate diphenhydramine as a high-risk medication in adults 65 and older. FRAME trial data (N=7,180) quantify how much clinical benefit is at stake: a 75% relative reduction in vertebral fracture risk over 24 months.

Prescribers and pharmacists reviewing the medication lists of patients on romosozumab should screen for diphenhydramine and offer second-generation antihistamine alternatives or non-pharmacologic sleep interventions wherever possible. Patients should be told, plainly, that a nighttime fall from a sedating OTC product can fracture the exact bones the monthly injection is working to protect.